Peptides for preventing or treating liver damage

Details Peptides for preventing or treating liver damage Peptides for preventing or treating liver damage

2011-07-26

2011-07-26

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C530S328000, C530S329000

Reexamination Certificate

active

07985734

ABSTRACT:
The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed.

REFERENCES:
patent: 5709995 (1998-01-01), Chisari et al.
patent: 1194986 (2005-03-01), None
patent: 1216075 (2005-08-01), None
patent: WO 03/097677 (2003-11-01), None
Encke et al. :“Development of a heterologous, multigenotype vaccine against hepatitis C virus infection” Europ. J. of Clin. Inves. vol. 37, pp. 396-406. 2007.
Ou-Yang et al. “Co-Delivery of GM-CSF Gene Enhances the Immune Responses of Hepatitis C Viral Core Protein-Expressing DNA Vaccine: Role of Dendritic Cells.” J. of Med. Virol. bol. 66, pp. 320-328. 2002.
Abrignani et al. Perspectives for a vaccine against hepatitis C virus. J. of Hepatology. VOI. 31, Supp. 1, pp. 259-263. 1999.
Houghton et al. Prospects for a Vaccine against the Hepatitis C virus. Nature, vol. 436, pp. 961-966. Aug. 2005.
Chi et al. “Cytokines secretion by peripheral blood mononuclear cells (PBMC) from hepatitis C patients after stimulation with synthetic peptides at the highly variable region (HVR1).” Chinese J. Exp. Clin. Virol. vol. 19, No. 3, pp. 279-281. Sep. 2005 (English Abstract included).
Bain et al. Effects of HCV Viral Dynamics on Treatment Design: Lessons Learned from HIV. American Journal of Gastroenterology. vol. 96, No. 10, pp. 2818-2828. 2001.
Hepatitis C. Mayoclinic.com. [online]. Retrieved on May 1, 2010. Retrieved from the Internet: <URL: http://www.myoclinic.com/health/hepatitis-C/DS00097/METHOD=print>. pp. 1-9.
Zhao et al. “DNA immunization of mice with plasmid encoding mimic epitopes of hypervariable region 1 of hepatitis C virus” Acta Academiae Mediciniae Militaris Tertiae. vol. 26, No. 24, pp. 2254-2257. Dec. 2004.
Choo et al. “Genetic organization and diversity of the hepatitis C virus” Proc. Natl. Acad. Sci. USA (88) Mar. 1991, p. 2451-2455.
Choo et al. “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome” Science (244) Apr. 21, 1989, p. 359-362.
Han et al. “Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3′ end” Proc. Natl. Acad. Sci. USA (88) Mar. 1991, p. 1711-1715.
Shirai et al. “T Cell Recognition of Hypervariable Region-1 from Hepatitis C Virus Envelope Protein with Multiple Class II MHC Molecules in Mice and Humans: Preferential Help for Induction of Antibodies to the Hypervariable Region” The Journal of Immunology (162) 1999, p. 568-576.
Manns et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2-b plus ribaviririn for initial treatment of chronic hepatitis C: a randomised trial. The Lancet (358) Sep. 22, 2001, p. 958-965.
Nelson et al. The Role of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in Chronic Hepatitis C. The Journal of Immunology (158) 1997, p. 1473-1481.
Wong et al. Liver-Derived CTL in Hepatitis C Virus Infection: Breadth and Specificity of Responses in a Cohort of Persons with Chronic Infection. The Journal of Immunology (160) 1998, p. 1479-1488.
Ruggieri et al. “Sensitization to Fas-Mediated Apoptosis by Hepatitis C Virus Core Protein” Virology (229) 1997, p. 68-76.
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/CN20061001176, 2007.

Affiliated with

Also associated with

Rating

Peptides for preventing or treating liver damage does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides for preventing or treating liver damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for preventing or treating liver damage will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680517